Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, has gone public with an IPO. Shares were priced at $18, below the expected range. and rose slightly to around $19 in their first morning of trading on May 6.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $11.37 |
|---|---|
| 52-week range | $10.45 - $21.69 |
| 50-day moving average | $14.15 |
| 200-day moving average | $17.05 |
| Wall St. target price | $15.79 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.5 from 2025-05-02
| 1 week (2025-04-28) | -15.81% |
|---|---|
| 1 month (2025-04-04) | -5.04% |
| 3 months (2025-02-06) | -28.39% |
| 6 months (2024-11-06) | -42.01% |
| 1 year (2024-05-06) | -20.36% |
|---|---|
| 2 years (2023-05-05) | -34.29% |
| 3 years (2022-05-05) | 18 |
| 5 years (2020-05-02) | N/A |
Valuing Bausch + Lomb Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch + Lomb Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bausch + Lomb Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6992. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bausch + Lomb Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Bausch + Lomb Corporation's PEG ratio in relation to those of similar companies.
Bausch + Lomb Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $552 million.
The EBITDA is a measure of a Bausch + Lomb Corporation's overall financial performance and is widely used to measure a its profitability.
To put Bausch + Lomb Corporation's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $4.8 billion |
|---|---|
| Gross profit TTM | $2.9 billion |
| Return on assets TTM | 0.96% |
| Return on equity TTM | -4.53% |
| Profit margin | -7.5% |
| Book value | $18.37 |
| Market Capitalization | $4.1 billion |
TTM: trailing 12 months
We're not expecting Bausch + Lomb Corporation to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Bausch + Lomb Corporation's shares have ranged in value from as little as $10.45 up to $21.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bausch + Lomb Corporation's is 0.539. This would suggest that Bausch + Lomb Corporation's shares are less volatile than average (for this exchange).
To put Bausch + Lomb Corporation's beta into context you can compare it against those of similar companies.
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .